About this raise
ViiT Health, with a valuation of $15 million, is raising funds on Wefunder. The company offers AI-assisted health monitoring services. The first product of ViiT Health, ViiT Gluco 1.0, is a one-of-a-kind glucometer that uses AI for the management of diabetes. ViiT Health has strategic alliances with Iasotek, Arrowhead Center, and Mexico City Innovation and Technology Agency and is supported by Monaco Foundry and a leading US Family Office. Luis Gomez founded ViiT Health in June 2021. The current crowdfunding campaign has a minimum target of $50,000 and a maximum target of $2,000,000. The campaign proceeds will be used for marketing and sales, product development, validation protocols, product certification, and software development.
Investment Overview
$530,600 - Total
Deal Terms
Total Commitments
- Platform
- Wefunder
- Start Date
- 10/08/2021
- Close Date
- 02/28/2022
$50,000
$2,000,000
$100
SAFE
Early Stage
RegCF
/ RegD 506(c)
$15,000,000
20%
Company & Team
Company
- Year Founded
- 2021
- Industry
- Healthcare & Pharmaceuticals
- Tech Sector
- Distribution Model
- B2B
- Margin
- Medium
- Capital Intensity
- High
Upgrade to gain access
-
$12.50 /month
billed annually - Free portfolio tracking, data-driven ratings, AI analysis and reports
- Plan Includes:
- Everything in Free, plus
- Company specific
Kingscrowd ratings and analyst reports
- Deal explorer and side-by-side comparison
- Startup exit and failure tracking
- Startup market filters and historical industry data
- Advanced company search ( with ratings)
- Get Edge Annual
Edge
Ratings 
Company Funding & Growth
Funding history
Founder Interview
ViiT Health CEO Luis Fernando on Making Diabetes Easier to Manage
Diabetes can have a major impact on patients’ lives. To maintain their health, diabetic individuals need to check glucose levels regularly. These checks are often done through invasive and painful methods like finger pricking.ViiT Health has developed Gluco 1.0, an affordable, reusable, and non-invasive product to measure glucose levels. Patients simply rest their finger inside Gluco 1.0, and it uses spectrometry to quickly and accurately assess glucose levels. We reached out to CEO Luis Fernando to learn why diabetes hits close to home for his team and how the recently established company has come so far.
Note: This interview was conducted over phone and email. It has been lightly edited for clarity and length.